Go to Top
INVENTOR LOGIN

Details

Project TitleArsenic Trioxide as a PARP-1 Inhibitor
Track Code2013-096
Short Description

The development of arsenic trioxide (ATO) as a radiation/chemotherapy sensitizer to enhance the radiation/chemotherapy effect in cells. 

Abstract

Researchers have demonstrated that arsenite inhibits DNA damage repair through inhibition of PARP-1 activity. 

 
Tagscancer, tumor, therapy
 
Posted DateMay 29, 2015

Researcher

Name
Laurie Hudson
Ke Jian Liu
Karen Cooper
Xixi Zhou

Manager

Name
Jovan Heusser

Background

Radiation therapy is a widely used clinical approach for treatment of solid tumors; however, radiation therapy can cause various adverse side effects.  Radiation sensitizers act in a number of ways to make cancer cells more susceptible to death by radiation than the surrounding healthy cells.  There is a present market need for an effective and clinically viable radiation sensitizer that enhances radiation effects and mitigates adverse side effects.  Similarly, enhancing the efficacy of chemotherapy and reducing its adverse effects would be highly desirable. 

Arsenic is a naturally occurring element that is present in food, soil, and water. Environmental or occupational exposures to arsenic are associated with both acute and chronic toxic effects in humans, including increased incidence of skin, lung, liver, and urinary tract cancers.  New studies at the University of New Mexico show that arsenic, in low micromolar concentrations, robustly inhibits DNA repair, enhancing the effects of radiation or chemotherapy in cells and animal models.

Technology Description

University of New Mexico researchers have developed arsenic trioxide (ATO) as a radiation/chemotherapy sensitizer to enhance the radiation/chemotherapy effect in cells.  Researchers have demonstrated that arsenite inhibits DNA damage repair through inhibition of PARP-1 activity. 

Advantages/Applications

  • Radiation sensitizer to enhance the radiation effect in cells
  • Enhancing the effects of common chemotherapeutic agents
  • Uncovered a novel underlying mechanism
  • Arsenic trioxide (ATO) is currently approved by FDA for treatment of certain leukemia cancer and may receive FDA approval more quickly as a repurposed drug compared to a new drug
  • Applications in cancer treatment, therapy and for the treatment of solid tumors
  • Potential to be re-purposed for treatment of other illness

INQUIRES

STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at amirabal@stc.unm.edu or 505-272-7886.

Files

File Name Description
US 2016/0184356 A1 Published Patent Application None Download